Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
$3.75
-0.7%
$4.06
$2.11
$21.60
$7.09M0.16519,160 shs10,748 shs
Allakos Inc. stock logo
ALLK
Allakos
$0.33
$0.31
$0.22
$1.56
$29.74M0.151.17 million shsN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$3.83
-2.5%
$4.38
$3.62
$9.18
$27.98M0.6157,312 shs14,036 shs
OnKure Therapeutics stock logo
OKUR
OnKure Therapeutics
$2.26
+5.1%
$2.93
$1.70
$20.00
$30.53M0.4110,279 shs245,247 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
-0.66%-2.22%+0.94%-55.04%-15.60%
Allakos Inc. stock logo
ALLK
Allakos
0.00%0.00%+0.77%+17.03%-76.82%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-2.54%-6.81%-18.51%-36.80%-45.67%
OnKure Therapeutics stock logo
OKUR
OnKure Therapeutics
+5.12%-2.59%-13.08%-54.07%+225,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
1.0847 of 5 stars
0.02.00.04.33.01.70.0
Allakos Inc. stock logo
ALLK
Allakos
4.5723 of 5 stars
3.15.00.04.72.72.51.3
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
4.1084 of 5 stars
3.23.00.04.62.52.50.6
OnKure Therapeutics stock logo
OKUR
OnKure Therapeutics
3.2562 of 5 stars
3.70.00.00.03.62.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
0.00
N/AN/AN/A
Allakos Inc. stock logo
ALLK
Allakos
2.20
Hold$2.00507.72% Upside
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
2.33
Hold$39.50931.33% Upside
OnKure Therapeutics stock logo
OKUR
OnKure Therapeutics
3.33
Buy$32.331,330.68% Upside

Current Analyst Ratings Breakdown

Latest ALBT, ALLK, OKUR, and KZR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/30/2025
OnKure Therapeutics stock logo
OKUR
OnKure Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
3/18/2025
OnKure Therapeutics stock logo
OKUR
OnKure Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $34.00
3/11/2025
OnKure Therapeutics stock logo
OKUR
OnKure Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$35.00 ➝ $30.00
2/28/2025
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Outperform
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
$1.37M5.18N/AN/A($17.22) per share-0.22
Allakos Inc. stock logo
ALLK
Allakos
N/AN/AN/AN/A$1.93 per shareN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$7M4.00N/AN/A$25.80 per share0.15
OnKure Therapeutics stock logo
OKUR
OnKure Therapeutics
N/AN/AN/AN/A$26.60 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
-$16.71M-$19.96N/AN/A-1,125.59%N/A-73.69%5/29/2025 (Estimated)
Allakos Inc. stock logo
ALLK
Allakos
-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%8/6/2025 (Estimated)
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$101.87M-$10.82N/AN/AN/AN/A-54.95%-46.11%8/12/2025 (Estimated)
OnKure Therapeutics stock logo
OKUR
OnKure Therapeutics
-$77.39M-$5.26N/AN/AN/AN/A-51.17%-47.11%8/12/2025 (Estimated)

Latest ALBT, ALLK, OKUR, and KZR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
N/A-$1.43N/A-$1.43N/AN/A
5/13/2025Q1 2025
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$2.56-$2.27+$0.29-$2.27N/AN/A
5/6/2025Q1 2025
OnKure Therapeutics stock logo
OKUR
OnKure Therapeutics
-$1.41-$1.19+$0.22-$1.19N/AN/A
3/25/2025Q4 2024 & Study Result
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$2.71-$2.77-$0.06-$2.77N/AN/A
3/10/2025Q4 2024
OnKure Therapeutics stock logo
OKUR
OnKure Therapeutics
-$0.86-$1.37-$0.51-$1.37N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
N/AN/AN/AN/AN/A
Allakos Inc. stock logo
ALLK
Allakos
N/AN/AN/AN/AN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
N/AN/AN/AN/AN/A
OnKure Therapeutics stock logo
OKUR
OnKure Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
N/A
0.11
0.11
Allakos Inc. stock logo
ALLK
Allakos
N/A
6.08
6.08
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
0.05
7.65
7.65
OnKure Therapeutics stock logo
OKUR
OnKure Therapeutics
N/A
23.71
23.71

Institutional Ownership

CompanyInstitutional Ownership
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
1.42%
Allakos Inc. stock logo
ALLK
Allakos
84.64%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
67.90%
OnKure Therapeutics stock logo
OKUR
OnKure Therapeutics
90.98%

Insider Ownership

CompanyInsider Ownership
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
37.30%
Allakos Inc. stock logo
ALLK
Allakos
16.12%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
10.40%
OnKure Therapeutics stock logo
OKUR
OnKure Therapeutics
2.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
51.89 million686,000Not Optionable
Allakos Inc. stock logo
ALLK
Allakos
19090.38 million74.94 millionOptionable
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
607.31 million6.62 millionNot Optionable
OnKure Therapeutics stock logo
OKUR
OnKure Therapeutics
N/A13.51 million2.75 millionN/A

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avalon GloboCare stock logo

Avalon GloboCare NASDAQ:ALBT

$3.74 -0.03 (-0.66%)
Closing price 05/27/2025 03:58 PM Eastern
Extended Trading
$3.71 -0.03 (-0.91%)
As of 07:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

Allakos stock logo

Allakos NASDAQ:ALLK

$0.33 0.00 (0.00%)
As of 05/15/2025

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Kezar Life Sciences stock logo

Kezar Life Sciences NASDAQ:KZR

$3.83 -0.10 (-2.54%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$3.82 -0.01 (-0.37%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

OnKure Therapeutics stock logo

OnKure Therapeutics NASDAQ:OKUR

$2.26 +0.11 (+5.12%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.33 +0.07 (+2.88%)
As of 05/27/2025 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.